Fenwick Represents Achieve Life Sciences in up to $354M Private Placement

Fenwick represented Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, in its private placement of its securities for gross proceeds up to approximately $354 million, before deducting placement agent fees and other expenses, including initial upfront funding of approximately $180 million and up to an additional approximately $174 million on exercise of milestone-driven warrants. More information can be obtained from Achieve Life Science’s announcement.

The Fenwick transaction team included corporate partners Amanda Rose and Chelsea Anderson, associates Arielle Trapp, Warren Pugash and Ross Willmot and law clerk Alexander Nohre.